Boosting Countermeasures: The U.S. and CEPI Tackle Rare Ebola Strain

The United States has pledged $50 million to the Coalition for Epidemic Preparedness Innovations (CEPI) to develop countermeasures against a rare Ebola strain affecting Africa. This funding will aid laboratory research, clinical trials, and manufacturing efforts, particularly targeting the Bundibugyo strain, which has led to significant outbreaks in the Democratic Republic of Congo and Uganda.

The U.S. government has announced a $50 million funding initiative aimed at combatting a rare strain of Ebola currently affecting Africa. The funds, directed to the Coalition for Epidemic Preparedness Innovations (CEPI), will focus on developing crucial medical countermeasures, according to the State Department.

This investment will support laboratory studies, clinical trials, and the manufacturing of medical countermeasures for the Bundibugyo strain of Ebola. With this latest contribution, the total funding from the State Department for the Ebola outbreak response reaches $270 million. CEPI, having already committed over $60 million, continues to explore additional vaccine candidates.

Dr. Richard Hatchett, CEO of CEPI, emphasized the urgency of the situation, noting the lack of licensed vaccines for the Bundibugyo virus. He stated that the funding will accelerate development efforts and strengthen global defenses against future epidemics. As the outbreak impacts the Democratic Republic of Congo and Uganda, U.S. agencies work closely with local and international partners to contain the virus effectively.